Research programme: CNS disorder therapeutics - Bristol Myers Squibb/Insitro
Latest Information Update: 04 Feb 2021
At a glance
- Originator Bristol-Myers Squibb; Insitro
- Class Antidementias
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Amyotrophic lateral sclerosis; Frontotemporal dementia
Most Recent Events
- 29 Oct 2020 Bristol Myers Squibb and Insitro collaborates to discover and develop therapies for ALS and FTD
- 29 Oct 2020 Early research in Amyotrophic lateral sclerosis in USA (unspecified route) prior to October 2020
- 29 Oct 2020 Early research in Frontotemporal dementia in USA (unspecified route) prior to October 2020